Neurocrine hands back 2 CNS gene therapy programs to Voyager
Neurocrine has handed back two discovery-stage gene therapy programs to Voyager Therapeutics, although the companies’ wider central nervous system-focused collaboration remains on track.
Neurocrine has handed back two discovery-stage gene therapy programs to Voyager Therapeutics, although the companies’ wider central nervous system-focused collaboration remains on track.
